MET Amplification in EGFR-Mutant Cancer: A Resistance Mechanism
MET amplification can provide an alternative route into downstream growth signalling in some EGFR-mutant lung cancers. It is important to distinguish gene copy-number gain, true amplification, protein expression and MET exon 14 skipping; they are not interchangeable findings.
Quick Answer
MET amplification can provide an alternative route into downstream growth signalling in some EGFR-mutant lung cancers. It is important to distinguish gene copy-number gain, true amplification, protein expression and MET exon 14 skipping; they are not interchangeable findings.
A Bypass-Signalling Concept
EGFR and MET are receptor tyrosine kinases that can converge on signalling routes such as MAPK and PI3K–AKT. Increased MET copy number may therefore reduce a tumour's dependence on EGFR alone.
That biology helps explain why MET amplification is examined in resistance work-ups, but it does not establish that MET is the sole cause of progression in an individual tumour.
What the Laboratory Is Measuring
Copy-number calls can be generated by sequencing, fluorescence in situ hybridisation or other validated methods. Thresholds, tumour purity and chromosome 7 context can affect how a result is classified.
MET amplification is different from a MET sequence variant or MET exon 14 skipping. The exact assay wording, estimated copy number and sample type should remain attached to any interpretation.
Key Takeaways
- ·MET amplification may act as a bypass mechanism in EGFR-driven cancer.
- ·Amplification, copy gain and MET exon 14 skipping are distinct findings.
- ·Use the complete report and clinical setting to interpret a resistance result.
Put these genes in pathway context
Frequently asked questions
What is the key idea in MET Amplification in EGFR-Mutant Cancer: A Resistance Mechanism?
MET amplification can provide an alternative route into downstream growth signalling in some EGFR-mutant lung cancers. It is important to distinguish gene copy-number gain, true amplification, protein expression and MET exon 14 skipping; they are not interchangeable findings.
What should be kept with the result or mechanism?
MET amplification may act as a bypass mechanism in EGFR-driven cancer. Amplification, copy gain and MET exon 14 skipping are distinct findings. Use the complete report and clinical setting to interpret a resistance result.
References
Continue Reading
MAPK Pathway Resistance: A Framework for Reading Resistance Reports
2 min read
EGFR C797S: What This Resistance Alteration Means
2 min read
EGFR T790M: A Gatekeeper Resistance Mutation
3 min read
EGFR, HER2, HER3 and HER4: The ERBB Receptor Family
2 min read
MET Exon 14 Skipping: A Splicing Change That Activates MET
3 min read
How Osimertinib Works: A Third-Generation EGFR Inhibitor
4 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
EGFR has 1000+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.